The Drive to ‘25

Jan 15, 2024

The drive to 2025 is underway!

With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect top-line data from five key EpicentRx clinical trials to read out.

For lead FDA Fast Tracked small molecule, RRx-001 (nibrozetone), these trials are the Phase 3 called REPLATINUM in small cell lung cancer (SCLC), the Phase 2b called KEVLARx for the prevention/amelioration of severe oral mucositis (SOM), and a Phase 1/2 in endometriosis at the University of Edinburgh, Scotland.

For lead TGF-β carrying oncolytic adenovirus, AdAPT-001, one trial called HAI MAINTENANCE will infuse AdAPT-001 through the hepatic artery to treat patients with liver-predominant colorectal cancer. In another called BETA PRIME, AdAPT-001 plus a checkpoint inhibitor will target sarcomas.

So, the itinerary has been set and we’re on a tight schedule to reach our ultimate destination, regulatory approval, hence it’s pedal to the metal time.

To learn more about our activities in Q4, check out our blog, press releases, and several new peer-reviewed publications linked below. Don’t forget to follow us on X and LinkedIn, too!

As always, thank you for taking the time to read and may the road rise up to meet you in 2024 and beyond,

The EpicentRx Team